Compare AURA & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AURA | PACB |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.6M | 521.8M |
| IPO Year | 2021 | 2010 |
| Metric | AURA | PACB |
|---|---|---|
| Price | $6.30 | $2.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $16.60 | $2.40 |
| AVG Volume (30 Days) | 869.6K | ★ 15.4M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $4.73 | $1.07 |
| 52 Week High | $9.54 | $3.44 |
| Indicator | AURA | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 55.33 |
| Support Level | $6.04 | $1.27 |
| Resistance Level | $7.18 | $2.73 |
| Average True Range (ATR) | 0.28 | 0.28 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 30.66 | 23.92 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.